Pfizer's Shakeup Means Less Money for Research

See allHide authors and affiliations

Science  11 Feb 2011:
Vol. 331, Issue 6018, pp. 658
DOI: 10.1126/science.331.6018.658

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The pharmaceutical giant Pfizer has announced it will lay off thousands of workers and cut its research and development budget by between $1.5 billion and $2 billion in 2012. That drastic decrease, industry observers say, reflects uncertainties facing many large drug companies about what role they should play—or even want to play—in basic drug research. Increasingly, they shop for the science they need, when they need it.